The Use of alpha-4 beta-7 integrin Inhibitors to Inhibit HIV Transmission and Infection

This invention involves the use of inhibitors of alpha-4 beta-7 (a4b7) integrin to inhibit HIV transmission/infection, as a prophylactic to inhibit onset of the acute stage of HIV infection or to treat HIV infection. The a4b7 integrin inhibitors were previously developed for use in other diseases, such as multiple sclerosis or inflammatory bowel disease.

a4b7 integrin is a multifaceted target for HIV infection and recent studies indicate that it is important for establishing HIV infection through multiple paths. Studies indicate that: 1) CD4 T-cells present in vaginal and anal mucosa have high levels of a4b7 integrin, making CD4 T-cells permissive to HIV infection; 2) a4b7 integrin is important for cell to cell transmission of HIV; 3) a4b7 integrin is used to dysregulate the host humoral response to HIV; and 4) HIV acts on a4b7 integrin through an epitope in V2 loop of GP120, identified as important for HIV vaccine protection. Additionally, primate studies indicate that a4b7 integrin inhibition of HIV infection preserves gut-associated lymphoid tissue (GALT) generally destroyed during the acute phase of HIV infection.

Potential Commercial Applications: Competitive Advantages:
  • Prevention and treatment of HIV infection
  • a4b7 integrin is a multifaceted target for HIV infection
  • Previously developed a4b7 integrin inhibitors can be used for a new purpose

Development Stage:
  • Pre-clinical
  • In vitro data available
  • In vivo data available (animal)


James Arthos (NIAID)  ➽ more inventions...

Diana Goode (NIAID)  ➽ more inventions...

Claudia Cicala (NIAID)  ➽ more inventions...

Anthony Fauci (NIAID)  ➽ more inventions...

Intellectual Property:
U.S. Pat: 9,441,041 issued 2016-09-13
U.S. Pat: 9,193,790 issued 2015-11-24
U.S. Pat: 9,896,509 issued 2018-02-20
US Application No. 60/920,880
US Application No. 60/873,884
US Application No. 12/518,035
US Application No. 15/227,879

Martinelli E, et al. PMID 23797688
Nawaz F, PMID 21383973
Cicala C, et al. PMID 19933330
Arthos J, et al. PMID 18264102

Collaboration Opportunity:

The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize alpha-4 beta-7 integrin inhibitors. For collaboration opportunities, please contact Bill Ronnenberg, JD/MIP, MS at 301-451-3522 or

Licensing Contact:
Christopher Kornak, J.D.
Phone: 240-627-3705

OTT Reference No: E-055-2007-0
Updated: Feb 28, 2014